These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17559752)

  • 21. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.
    Lipka LJ
    Cardiovasc Drug Rev; 2003; 21(4):293-312. PubMed ID: 14647533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia.
    Yamaoka-Tojo M; Tojo T; Kosugi R; Hatakeyama Y; Yoshida Y; Machida Y; Aoyama N; Masuda T; Izumi T
    Lipids Health Dis; 2009 Oct; 8():41. PubMed ID: 19821987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
    Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
    Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
    Gagné C; Bays HE; Weiss SR; Mata P; Quinto K; Melino M; Cho M; Musliner TA; Gumbiner B;
    Am J Cardiol; 2002 Nov; 90(10):1084-91. PubMed ID: 12423708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk.
    Moysich KB; Freudenheim JL; Baker JA; Ambrosone CB; Bowman ED; Schisterman EF; Vena JE; Shields PG
    Mol Carcinog; 2000 Jan; 27(1):2-9. PubMed ID: 10642431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of apolipoprotein E genotypes with lipid levels and coronary risk.
    Bennet AM; Di Angelantonio E; Ye Z; Wensley F; Dahlin A; Ahlbom A; Keavney B; Collins R; Wiman B; de Faire U; Danesh J
    JAMA; 2007 Sep; 298(11):1300-11. PubMed ID: 17878422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E genotypes and their relation to lipid levels in a rural South African population.
    Masemola ML; Alberts M; Urdal P
    Scand J Public Health Suppl; 2007 Aug; 69():60-5. PubMed ID: 17676504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
    Davidson MH; McGarry T; Bettis R; Melani L; Lipka LJ; LeBeaut AP; Suresh R; Sun S; Veltri EP
    J Am Coll Cardiol; 2002 Dec; 40(12):2125-34. PubMed ID: 12505224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders.
    Ferreira CN; Carvalho MG; Fernandes AP; Lima LM; Loures-Valle AA; Dantas J; Janka Z; Palotás A; Sousa MO
    Neurochem Int; 2010 Jan; 56(1):177-82. PubMed ID: 19819279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
    Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
    Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
    Knopp RH; Gitter H; Truitt T; Bays H; Manion CV; Lipka LJ; LeBeaut AP; Suresh R; Yang B; Veltri EP;
    Eur Heart J; 2003 Apr; 24(8):729-41. PubMed ID: 12713767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) Mass Levels Increase Significantly According to
    Moriarty PM; Varvel SA; Gordts PL; McConnell JP; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):580-588. PubMed ID: 28062489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.